Ignite Creation Date:
2024-05-06 @ 1:15 PM
Last Modification Date:
2024-10-26 @ 1:11 PM
Study NCT ID:
NCT03973918
Status:
TERMINATED
Last Update Posted:
2024-03-06
First Post:
2019-05-31
Brief Title:
Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG
Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study Overview
Official Title:
A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor
Status:
TERMINATED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
NCI decided to terminate ABTC Consortium due to NCI moving in different direction for Brain Cancer
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BRAF
Brief Summary:
The goal of this study is to estimate the efficacy of encorafenib and binimetinib as measured by radiographic response in recurrent high-grade primary brain tumors
Detailed Description:
Primary Objective Estimate the efficacy of combination treatment with encorafenib and binimetinib as measured by response rate RANO criteria in patients with recurrent BRAF V600EK-mutated malignant glioma MG and anaplastic pleomorphic xanthoastrocytoma PXAs
Secondary Objectives
1 Estimate efficacy as measured by progression-free survival in subjects with recurrent malignant glioma or anaplastic PXA containing a BRAF-V600EK mutation who receive drug
2 Evaluate duration of response in subjects who have a partial or complete response
3 Quantify the time-to-response among subjects who have a radiologic response
4 Estimate efficacy as measured by overall survival in subjects with recurrent malignant glioma or anaplastic PXA containing a BRAF-V600EK mutation who receive drug
5 Characterize the toxicity profile of the combination of encorafenib and binimetinib in this patient population
There are two arms medical and surgical Subjects on the surgical arm must have a high-grade glioma or a known BRAF-mutated low-grade glioma with high clinical suspicion for progression to high-grade
Medical Following enrollment patients will receive encorafenib and binimetinib at the FDA-approved dose of 450 mg of encorafenib once daily and the FDA-approved dose of 45 mg of binimetinib twice daily separated by 12 hours continuously in 28-day cycles until progression or unacceptable toxicity Patients will be followed by routine blood work and general and neurological examination A brain MRI will be performed prior to every odd-numbered cycle every 8 weeks Response will be assessed by RANO criteria Patients may remain on study and receive treatment until progression or other reason
Surgical These subjects will take encorafenib and binimetinib in combination at their FDA-approved doses for 10-14 days prior to surgery The last dose of both drugs will be administered two hours prior to surgery Specimens will be collected during surgery After surgery the subjects will not take further encorafenib or binimetinib until a study visit to assess their neurological exam physical exam and performance status at 2-6 weeks post-operatively At time of restarting combination treatment subjects will follow the schedule for the medical cohort and will continue treatment until progression
Secondary Objectives
1 Estimate efficacy as measured by progression-free survival in subjects with recurrent malignant glioma or anaplastic PXA containing a BRAF-V600EK mutation who receive drug
2 Evaluate duration of response in subjects who have a partial or complete response
3 Quantify the time-to-response among subjects who have a radiologic response
4 Estimate efficacy as measured by overall survival in subjects with recurrent malignant glioma or anaplastic PXA containing a BRAF-V600EK mutation who receive drug
5 Characterize the toxicity profile of the combination of encorafenib and binimetinib in this patient population
There are two arms medical and surgical Subjects on the surgical arm must have a high-grade glioma or a known BRAF-mutated low-grade glioma with high clinical suspicion for progression to high-grade
Medical Following enrollment patients will receive encorafenib and binimetinib at the FDA-approved dose of 450 mg of encorafenib once daily and the FDA-approved dose of 45 mg of binimetinib twice daily separated by 12 hours continuously in 28-day cycles until progression or unacceptable toxicity Patients will be followed by routine blood work and general and neurological examination A brain MRI will be performed prior to every odd-numbered cycle every 8 weeks Response will be assessed by RANO criteria Patients may remain on study and receive treatment until progression or other reason
Surgical These subjects will take encorafenib and binimetinib in combination at their FDA-approved doses for 10-14 days prior to surgery The last dose of both drugs will be administered two hours prior to surgery Specimens will be collected during surgery After surgery the subjects will not take further encorafenib or binimetinib until a study visit to assess their neurological exam physical exam and performance status at 2-6 weeks post-operatively At time of restarting combination treatment subjects will follow the schedule for the medical cohort and will continue treatment until progression
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| UM1CA137443 | NIH | None | httpsreporternihgovquickSearchUM1CA137443 |